Related Experiment Video

Updated: Jun 9, 2025

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on: June 26, 2019

7.9K

ARAF Amplification in Small-Cell Lung Cancer-Transformed Tumors Following Resistance to Epidermal Growth Factor

Ryo Kimura1,2, Yuta Adachi1, Kentaro Hirade1

  • 1Division of Molecular Therapeutics, Aichi Cancer Center Research Institute, Nagoya 464-8681, Japan.

Cancers
|October 26, 2024
PubMed
Abstract

Insights

ARAF gene amplification is a newly identified mechanism of resistance in EGFR-mutant non-small cell lung cancer (NSCLC). This amplification, found in 5-8% of resistant tumors, may also play a role in transformation to small-cell lung cancer (SCLC).

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have improved outcomes for EGFR-mutant non-small cell lung cancer (NSCLC).
  • Acquired resistance to EGFR-TKIs is a significant clinical challenge, often involving reactivation of MAPK signaling.
  • ARAF gene amplification is a resistance mechanism that activates MAPK signaling, but its clinicopathologic characteristics are poorly understood.

Purpose of the Study:

  • To investigate the clinicopathologic characteristics of ARAF gene amplification in EGFR-mutant NSCLC resistant to EGFR-TKIs.
  • To determine the frequency of ARAF amplification in TKI-resistant NSCLC.
  • To explore the association between ARAF amplification and histological transformation to small-cell lung cancer (SCLC).

Main Methods:

  • Retrospective analysis of re-biopsied samples from EGFR-mutant NSCLC patients resistant to EGFR-TKIs.
  • ARAF amplification detected using gene copy number assay.
  • RNA sequencing performed on ARAF-amplified tumors and those with histologic transformation to SCLC.

Main Results:

  • ARAF amplification was identified in 5/97 patients resistant to first-generation EGFR-TKIs and 4/48 patients resistant to Osimertinib.
  • Amplification was predominantly observed in female patients with EGFR exon 19 deletions.
  • All amplified tumors retained the original EGFR mutation; two cases showed transformation to SCLC.

Conclusions:

  • ARAF amplification occurs in 5-8% of EGFR-TKI-resistant NSCLC tumors.
  • The findings suggest a potential role for ARAF in the transformation of NSCLC to SCLC.
  • Further research is warranted to elucidate the role of ARAF in SCLC transformation.
Keywords:
ARAF amplificationepidermal growth factor receptor tyrosine kinase inhibitorresistancesmall-cell lung cancertransformation

More Related Videos

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure09:38

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

8.8K
A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds13:34

A Combined 3D Tissue Engineered In Vitro/In Silico Lung Tumor Model for Predicting Drug Effectiveness in Specific Mutational Backgrounds

Published on: April 6, 2016

10.2K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K